Analysis of current multiple sclerosis registries
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Patient registries are valuable because they provide data that cannot be captured in any other way. Observations from registry studies are particularly informative if multiple registries confirm similar findings. A selection of multiple sclerosis (MS) registry studies were reviewed, and results and consistency of those studies are presented.
Methods: A panel of experts analyzed the study findings of established MS registries and presented their conclusions on the overall results and consistency of those studies.
Results: A review of evidence from MS registry studies reveals similar findings with respect to patterns of disability progression, predictors of disability progression, and changes in lifespan. Several registries show that progression after Expanded Disability Status Scale (EDSS) 4 occurs at a predictable rate, and once EDSS 4 is reached, subsequent progression rates are similar regardless of the type of MS at onset. Clinicians, payers, and patients need to understand that MS may shorten life expectancy. The mortality data derived from registries reveal higher death rates in patients with MS compared with the general population, indicating that MS is an important public health issue.
Conclusions: The key findings in registries should be utilized in conjunction with data from clinical trials to optimize treatment and improve long-term outcomes.
Footnotes
-
- BCMS
- British Columbia Multiple Sclerosis
- CDMS
- clinically definite multiple sclerosis
- DMT
- disease-modifying therapy
- EDMUS
- European Database for Multiple Sclerosis
- EDSS
- Expanded Disability Status Scale
- IFN
- interferon
- MS
- multiple sclerosis
- NYSMSC
- New York State Multiple Sclerosis Consortium
- PPMS
- primary progressive multiple sclerosis
- PRMS
- primary relapsing multiple sclerosis
- RRMS
- relapsing-remitting multiple sclerosis
- SPMS
- secondary progressive multiple sclerosis.
-
This Neurology® supplement is not peer-reviewed. Information contained in this Neurology® supplement represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Registry studies of long-term multiple sclerosis outcomesDescription of key registriesBarrie J. Hurwitz et al.Neurology, December 27, 2010 -
Articles
Longitudinal follow-up of “benign” multiple sclerosis at 20 yearsAna-Luiza Sayao, Virginia Devonshire, Helen Tremlett et al.Neurology, February 12, 2007 -
Articles
Disability profile of MS did not change over 10 years in a population-based prevalence cohortS. J. Pittock, W. T. Mayr, R. L. McClelland et al.Neurology, February 23, 2004 -
Article
Psychiatric comorbidity is associated with disability progression in multiple sclerosisKyla A. McKay, Helen Tremlett, John D. Fisk et al.Neurology, March 09, 2018